|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
S100A11 overexpression has been reported in a number of cancers including papillary thyroid carcinoma, colon, pancreatic, and breast cancer.
|
30662594 |
2018 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This study aimed to identify the function of S100A11 associated with cell proliferation and invasion in gastric cancer.
|
30662594 |
2018 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Collectively, our results demonstrated that EIF3C overexpression is a potential target of angiogenesis for treatment with exosome inhibitor or S100A11 reduction to suppress HCC angiogenesis and tumorigenesis.
|
29568350 |
2018 |
|
Degenerative polyarthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
S100A11 was significantly increased in synovial fluid (p < 0.0001) but not in serum (p = 0.158) from patients with RA compared to patients with OA when adjusted for age and sex.
|
28446208 |
2017 |
|
Malignant neoplasm of stomach
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We detected upregulated S100A2, S100A6, S100A10, and S100A11 expression and downregulated S100P and S100B expression in GC.
|
25266115 |
2015 |
|
Papillary thyroid carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
S100A6, S100A11 and its putative interaction partner annexin A1 showed the highest overexpression in PTC compared to normal thyroid.S100A13 was also elevated in PTC.
|
25880590 |
2015 |
|
Intrahepatic Cholangiocarcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The S100 family members on chromosome 1q21 were extensively upregulated in ICC, and S100A11 had the greatest degree of upregulation in ICC.
|
25712376 |
2015 |
|
Stomach Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We detected upregulated S100A2, S100A6, S100A10, and S100A11 expression and downregulated S100P and S100B expression in GC.
|
25266115 |
2015 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Using MDA-MB-231 as a model breast cancer cell line, we provide evidence that PFN1 overexpression is associated with alterations in the expression of proteins that have been functionally linked to cell proliferation (FKPB1A, HDGF, MIF, PRDX1, TXNRD1, LGALS1, STMN1, LASP1, S100A11, S100A6), survival (HSPE1, HSPB1, HSPD1, HSPA5 and PPIA, YWHAZ, CFL1, NME1) and motility (CFL1, CORO1B, PFN2, PLS3, FLNA, FLNB, NME2, ARHGDIB).
|
25454514 |
2014 |
|
Degenerative polyarthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Bioinformatics analysis showed increased mRNA expression of Damage-Associated Molecular Patterns (DAMPs): HMGA, HMGB, HMGN, SRY, LEF1, HMGB1, MMPs, and HMG/RAGE-interacting molecules (spondins and S100A4, S100A10, and S100A11) in human OA-affected cartilage as compared with normal cartilage.
|
24905701 |
2014 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Using MDA-MB-231 as a model breast cancer cell line, we provide evidence that PFN1 overexpression is associated with alterations in the expression of proteins that have been functionally linked to cell proliferation (FKPB1A, HDGF, MIF, PRDX1, TXNRD1, LGALS1, STMN1, LASP1, S100A11, S100A6), survival (HSPE1, HSPB1, HSPD1, HSPA5 and PPIA, YWHAZ, CFL1, NME1) and motility (CFL1, CORO1B, PFN2, PLS3, FLNA, FLNB, NME2, ARHGDIB).
|
25454514 |
2014 |
|
Papillary thyroid carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We found that the S100A11 gene expression is frequently up-regulated in PTC, anaplastic thyroid carcinoma, but not in follicular thyroid carcinoma.
|
23928665 |
2013 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Furthermore, the overexpression of S100A11 can promote HCC cell invasiveness, whereas siRNA against S100A11 can suppress the invasiveness of HCC cells stably transfected with EGFRvIII.
|
24376686 |
2013 |
|
Degenerative polyarthritis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Chondrocyte RAGE expression and S100A11 release are stimulated by IL-1beta in vitro and increase in OA cartilage in situ.
|
18523305 |
2008 |
|
Degenerative polyarthritis
|
0.030 |
Biomarker
|
disease |
LHGDN |
Chondrocyte RAGE expression and S100A11 release are stimulated by IL-1beta in vitro and increase in OA cartilage in situ.
|
18523305 |
2008 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
LHGDN |
S100A6 and S100A11 can discriminate significantly between the two primary tumor entities, CRC and HCC, whereas S100A6 allows the discrimination of metastases and HCC.
|
19048101 |
2008 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer.
|
15138568 |
2004 |
|
Secondary malignant neoplasm of lymph node
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
S100A11 gene expression was clearly up-regulated in specimens from patients with lymph node metastases relative to those from patients without lymph node metastases.
|
15138568 |
2004 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer.
|
15138568 |
2004 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Two of these genes, L19 and MLN70, were previously reported to be overexpressed in breast cancer.
|
10752678 |
2000 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Two of these genes, L19 and MLN70, were previously reported to be overexpressed in breast cancer.
|
10752678 |
2000 |
|
Congenital chromosomal disease
|
0.020 |
Biomarker
|
group |
BEFREE |
Furthermore, we present a protocol for assessment of chromosomal aberrations after depletion of S100A11 that illustrate the apparent involvement of S100A11 in genome integrity.
|
30710290 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We also demonstrated the S100A11 on tumour growth in GBM using an orthotopic tumour xenografting.
|
31430050 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We also demonstrated the S100A11 on tumour growth in GBM using an orthotopic tumour xenografting.
|
31430050 |
2019 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We explored the role of S100A11 in the proliferation and apoptosis of pancreatic cancer cell line PANC-1 and the potential mechanisms involving the TGF-β<sub>1</sub>/SMAD4/p21 pathway.
|
29922945 |
2019 |